Kura Oncology, Inc.
Long

Kura Oncology, Inc. (KURA) Advances Cancer Drug Pipeline

136
Kura Oncology, Inc. (KURA) is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its pipeline focuses on small-molecule therapies designed to target genetic mutations and signaling pathways that drive tumor growth. Kura’s growth is fueled by advancing clinical trials, strong potential in hematologic malignancies and solid tumors, and partnerships that support the development of transformative oncology treatments.

On the chart, a confirmation bar with rising volume highlights bullish momentum. The price has entered the momentum zone after breaking above the .236 Fibonacci level. A trailing stop can be set just below this Fibonacci line using the Fibonacci snap tool, helping traders secure profits while allowing room for further upside potential.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.